NCT05891366View on ClinicalTrials.gov

Single Ascending Dose Study of WAL0921 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2023

Primary Completion Date

January 9, 2024

Study Completion Date

January 9, 2024

Conditions
Healthy
Interventions
DRUG

WAL0921

Investigational product WAL0921

DRUG

Placebo

Placebo product

Trial Locations (1)

78744

PPD Pharmacology Unit, Austin

Sponsors

Lead Sponsor

Walden Biosciences
All Listed Sponsors
lead

Walden Biosciences

INDUSTRY